“
“BACKGROUND: The optimal extent of resection for surgical treatment of lesional epilepsy is a controversial issue.

OBJECTIVE: For patients with mesial temporal lobe lesions visible on magnetic resonance imaging, we compared the

surgical outcome of selective lesionectomy with that of standard anterior temporal lobectomy (ATL) and amygdalohippocampectomy.

METHODS: We conducted a retrospective analysis of the seizure outcome of 40 patients treated for lesional mesial temporal lobe epilepsy between 1993 and 2008. Before 2006, patients were managed by ATL (n = 29) and from selleck compound 2006 onward, by selective lesionectomy via the transsylvian-transcisternal approach (n = 11).

RESULTS: The postoperative seizure-free rates for the 2 groups were comparable: 93% (27/29) for the ATL group and 91% (10/11) for the selective lesionectomy group (P = .814). In both groups, patients with persistent seizures commonly showed incomplete lesion Z VAD FMK resection, with complete resection often improving seizure outcome. Postoperative visual field defects were more common in the ATL group (21%) than in the selective lesionectomy group (0%) (P = .102).

CONCLUSION: Transsylvian-transcisternal selective lesionectomy is an effective and safe therapeutic modality in children with lesional mesial temporal lobe epilepsy. Completeness

of resection is an important variable for seizure control regardless of surgical modality.”
“The potential of fibroblast growth factor-2 (FGF-2) to stimulate osteoprogenitors in aging bone was investigated. Previous work showed a decrease in bone formation in cell cultures derived from bone of elderly female patients, but not in cells from age-matched male or younger female patients, with transforming growth factor beta increasing bone formation but not increasing osteoprogenitors.

In the present study, FGF-2 was shown to significantly stimulate, in a dose-dependent manner, Sclareol proliferation of mesenchyme-derived progenitor cells from bones of young and old mouse and humans. In proliferation assays, human cells were more responsive to lower concentrations (0.0016 ng/mL) of FGF-2 than mouse cells, but proliferation was less in cells from older bone. Immunofluorescence microscopy revealed that FGF-2 increased and prevented the decline in cells expressing activated leukocyte cell adhesion molecule, a novel marker for early lineage osteoblasts, but not alpha-smooth muscle actin. FGF-2 may have therapeutic potential for stimulating osteoblast progenitors in aging.”
“The development of L-dopa-induced dyskinesia (LID) remains a major problem in the long-term treatment of Parkinson’s disease (PD). This study aimed to assess the effect of the multitargeting molecule BN82451 on LID and to measure striatal mRNA expression of several genes in a rat model of PD.